FP588: A Potential Drug Target and Biomarker (G92973)

Target Name: FP588

NCBI ID: G92973

FP588

Other Name(s): Uncharacterized LOC92973

FP588: A Potential Drug Target and Biomarker

FP588 (Uncharacterized LOC92973) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the LOC92973 family, which is characterized by the presence of a unique N-terminal region that is involved in protein-protein interactions. While the exact function of FP588 is not yet well understood, it is potential drug target or biomarker.

Expression and Localization

FP588 is expressed in a variety of tissues and organs, including the brain, heart, and kidneys. It is found in the brain, where it is located in the protein fractal (PDF) domain and is involved in the formation of the outer self-standing membrane (OM) and the inner self-standing membrane (IM) of neurons. It is also found in the heart, where it is involved in the formation of the intercellular junctions (ICJ) and the endothelium (ENDR). Additionally, it is found in the kidneys, where it is involved in the regulation of ion transport and blood pressure.

Structure and Function

The structure of FP588 is unique, as it has a conserved N-terminus that is involved in protein-protein interactions. It has a molecular weight of approximately 11 kDa and consists of two distinct domains: an N-terminal domain and a C-terminal domain. The N-terminal domain has a putative N-methylation site and is involved in protein-protein interactions. The C-terminal domain has a unique structural feature, as it has a long free alanine residue, which is involved in the formation of a distinct protein-protein interaction network.

FP588 is involved in a variety of cellular processes, including cell signaling, cell adhesion, and neurotransmission. It is a negative regulator of the protein Shc/FAK, which is involved in cell signaling and survival. Additionally, FP588 is involved in the regulation of the protein Tau, which is involved in the formation of neurodegeneration.

Drug Target Potential

FP588 is a potential drug target due to its unique structure and function. The N-terminal domain has a putative N-methylation site, which could make it a target for small molecules that can modulate the activity of the protein. Additionally, the C- terminal domain has a unique structural feature that could make it a target for antibodies that can specifically recognize and interact with it.

Biomarker Potential

FP588 is a protein that is expressed in a variety of tissues and organs, making it a potential biomarker. Its unique structure and function make it a potential target for small molecules and antibodies that can be used to diagnose and treat a variety of diseases. For example, FP588 could be used as a biomarker for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, FP588 could be used as a biomarker for diseases that involve the regulation of ion transport, such as heart failure and hypertension.

Conclusion

FP588 is a unique protein that is expressed in various tissues of the body. Its structure and function make it a potential drug target and biomarker. The N-terminal domain has a putative N-methylation site and the C-terminal domain has a unique structural feature that could make it a target for small molecules and antibodies. Further research is needed to fully understand the function of FP588 and its potential as a drug target and biomarker.

Protein Name: Uncharacterized LOC92973

The "FP588 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FP588 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets